Share Name Share Symbol Market Type Share ISIN Share Description
Supreme Plc LSE:SUP London Ordinary Share GB00BDT89C08 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -7.00 -3.52% 192.00 106,749 15:15:26
Bid Price Offer Price High Price Low Price Open Price
190.00 194.00 195.00 192.00 195.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 122.25 12.96 8.90 21.6 224
Last Trade Time Trade Type Trade Size Trade Price Currency
16:25:45 O 2,632 190.00 GBX

Supreme (SUP) Latest News

More Supreme News
Supreme Investors    Supreme Takeover Rumours

Supreme (SUP) Discussions and Chat

Supreme Forums and Chat

Date Time Title Posts
17/9/202118:24Supreme imports floats on AIM200
11/1/200123:00SPERFRAME a Super Shell ?-
11/1/200123:00SUPERFRAME a Super Shell ?-

Add a New Thread

Supreme (SUP) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Supreme trades in real-time

Supreme (SUP) Top Chat Posts

Supreme Daily Update: Supreme Plc is listed in the Support Services sector of the London Stock Exchange with ticker SUP. The last closing price for Supreme was 199p.
Supreme Plc has a 4 week average price of 192p and a 12 week average price of 192p.
The 1 year high share price is 222.50p while the 1 year low share price is currently 142p.
There are currently 116,627,074 shares in issue and the average daily traded volume is 70,473 shares. The market capitalisation of Supreme Plc is £223,923,982.08.
trcml: "Price points are a bit of shock, makes me think how much we have been screwed over by retailers in the past. EG the price comparison Holland and Barrett to Sea lions." For a few years the small shop in which i had an interest sold VMS (vitamins, minerals, supplements). We didn't stock many brands, just those we considered worth taking. Depending upon the brand, the mark-up for local shopkeepers can be substantial. One brand in particular prides itself in offering 50% markup; and that's before bulk purchasing. Retailers buying large quantities would probably get 60-70%+. I liken VMS manufacturers as equivalent to drug barons; product costs very little compared to what each tablet / capsule can be sold for to the consumer for. Also the ting about VMS is that they are addictive: consumers tend to be brand loyal and buy weekly or monthly. Myself i take a VM tablet and a garlic capsule every day, have done for more than 40 years. I buy direct from the manufacturer using the trade contact from before (manufacturers can sell via websites direct to the end consume); i get a good discount on what what I'd have to pay a shop if I only bought 1 month's supply at a time. Even so the manufacturer must still be making a good product.
chilltime: Miti Yes good to share views. It was due to IPO 2-3 years ago, I take it CEO not ready and once the Vape business expanded it was time to press the button as extra value was there. Not a chance in hell the they are here to just spin out divi's and try to expand from cashflow. It was clearly stated they can grow quicker via a PLC which means only one thing. I can't see how they can go 32 SKU's, to 100 next year to 300 and become a mini Holland and Barrett in a few years by forking out 50% to a divi and trying to do that from the leftovers. Plus the other expansions and opportunities they foresee If that was the plan there was absolutely no need to come to the market now. They have identified a market they have brands so the obvious route is to establish and expand rapidly while others are asleep. If they are not going to do that I for one am not interested. It's their drive, strategy and rapid expansion that is the attraction. So I'd look forward to a big raise to expand rapidly it makes it far more attractive for little dilution and creates far more value for the CEO and shareholders. Funds won't be interested in slowly slowly, the opportunity is there, go get it, that appears to be the SUP ethos anyway.
miti 1000: chilltime, I think they have made small acquisitions and will continue to do so while they build their Vape and vitamin ranges . They have the capacity to expand their products lines already. Fwiw, I listened to that presentation about 20times in full ! I don't disagree that they will want to raise funds in future but I certainly do not believe it will be anytime soon or anywhere near the prices you have suggested. Sandy has a 56% stake in Supreme and will not want to raise money while the share price is much below 3 quid imo. Thanks for your views.
chilltime: Miti They only raised £7.5m and have spent some since on acquisitions. They talked plan to do M and A. Quote, wellbeing companies make no money in the £5m to 15m revenue area. Hence they have acquired companies from liquidations and will need growth. They have growth and expansion plans and the CEO states divis would not be in play if the growth option is there, which some here have already already stated, 'prefer growth to divis. Check the comprehensive video presentation Absolutely no need to come to the market if the plan was to expand from cash paying divis each year. The funds will want growth, they have identified the rip off in the market, the competition at the high end and the market opportunity at the value price end with little competition. They have strategy to remove middle men and up margins, EG they have been surprised to find how cheap it is to produce vitamins compared to what those in the market have been selling them for. Home Bargains and the like have been rapid success stories due to the value. Supreme look like a Sports direct growth story in segments they have spotted, they have the outlets and history and now they want to bring the identified markets into the value sector. Further they seem to do so in non plastic biodegradable packaging. So to think they are not here to get the cash backing and expand rapidly would be a mistake I believe.
chilltime: Had a look, interesting company and a likeable dynamic team. Thoughts Repeated talk about growth M and A, factory available can double vape capacity and so on. They specifically state can grow faster as a public company, that will be down to the availability of cash via raises. 5 funds in up to under 5% not much else on the major holder front other than them. Clearly a supply, which is undoubtedly one of the funds that got in. Berenberg connected, Berenberg target price £2.20 then £2.30, it hit their first target quickly, so not really surprising that a fund is selling. They want to expand they want to acquire companies, they came to the market. So clearly they will be back for more cash, imo within the next 6 months. £10m to £20m would be my guess £20m more likely than £10m, dilution would be low and I imagine the funds would be keen for them to rapidly progress. So I would be keen to see a fund raise of a material amount to crack on as the prospects look very good, get those brands going and margins up by removing middle men. At what price that would be is down to the next few months and timing of the raise. As it stands £1.60 to £1.80 given the higher revenue since the £1.34 raise. £2 and over seems a long shot unless it goes mad on new products and the expansion of retail outlets recently. Flies in the ointment. Unknowns re how the goods they import will be impacted on availability and price, rising costs for whey as mentioned re the supplements. UK manufacturing, a fab plus. Price points are a bit of shock, makes me think how much we have been screwed over by retailers in the past. EG the price comparison Holland and Barrett to Sea lions.
trcml: The point of my wondering has been missed. A difference exists surely between the editor of SW writing about a company and (1) ending by saying he is buying in and (2) having bought some time ago, for example £1 for SUP, and waiting until his buy price has doubled (or risen substantially) before writing it up or the benefit of others. Small co sis generally are market-maker influenced. A write up in. atisheet is bound to trigger a rise as the MM ups the price to deter buyers. But most buyers miss the point that a share price rise is not necessarily a good thing. It is wen MM educe the share price to deter sellers that is the time to buy - either way presupposing the company would make a good investment.
robbnw: I actually think the opposite , SCSW editor has a fixed amount to invest . His role and the success of his business is to create value for investors Subscribers will see that he recommends a number of shares and can not invest in them all . If he chooses to invest in SUP as one of the few , to me that is an even better sign of confidence . Forget what he makes on his small investment . The key is what his subscribers make We will see re SUP I for one am confident . I would buy on any drop
simon gordon: Setting up a nutrition supplement company nowadays is easy. Quite a few companies offer the service, here's an example: Https://www.privatelabelnutrition.co.uk/ The gear that Supreme market is bog standard. For quality gear you have to go to firms like Biocare (used to be on AIM) or in America; Thorne Research, Allergy Research, etc. The top end is quite competitive but more cutting edge and of course higher quality. The bottom end is all about getting distribution and price. Amazon is an easy place to pitch your brand. Supreme could make some bread in the nutrition field but it's a tough and ultra crowded market. Branding is all and pitching to your audience is key. Supreme's looks cheap and cheerful. Holland and Barrett have a big lock on a lot of that part of the market with specials galore. Also Nature's Best is quite a switched on low cost brand that has some interesting product pitched mid to low range. Higher Nature as well is a good little British nutrition brand. Sealions is an unusual name for a nutrition wellness brand - maybe it will catch on.
masurenguy: Supreme is good value after deal, says Berenberg Consumer goods manufacturer and supplier Supreme (SUP) has made its first acquisition since listing earlier this year and Berenberg says the deal has ‘excellent strategic rationale’. Analyst Owen Shirley retained his ‘buy’ recommendation and increased the target price from 220p to 230p on the stock after its purchase of Vendek, a small batteries and lighting distributor in Ireland for €1.8m. Shirley said ‘the deal has excellent strategic rationale and [we] expect there to be a significant number of further accretive bolt-on deals that Supreme could deliver over the coming years’. The analyst said Supreme currently trades at 15x estimated March 2022 price/earnings and ‘we continue to believe that this remains good value for a cash-generative business generating double-digit earnings growth, with scope to drive further upgrades to estimates both organically and through additional bolt-on M&A’. The shares started trading in February priced at 134p. https://citywire.co.uk/investment-trust-insider/news/expert-view-saga-dechra-frontier-developments-serco-and-supreme/a1519195
patient fox: Berenberg initiated coverage on batteries and lightbulbs distributor Supreme at 'buy' on Tuesday, stating the group was "supremely well positioned". Berenberg said Supreme, which owns, licenses and distributes a variety of consumer brands, has repeatedly expanded into new product categories for more than a decade and had become "a key supplier" for customers like B&M and local convenience stores. The German bank also highlighted that Supreme now boasts the largest vaping brand in the UK, and noted that it was continuing to "add strings to its bow", with recent entries into the sports nutrition, vitamin and household product markets. "With the shares offering a 3.6% dividend yield and double-digit earnings growth, we think they remain good value," said Berenberg, which slapped the stock with a 220.0p target price. Berenberg also stated that Supreme generates "outstanding" returns on invested capital, 59% in 2020 and still trending upwards, due to the asset-light nature of its distribution business and the efficiency with which it has set up its own manufacturing capabilities in vaping and sports nutrition. Lastly, the analysts acknowledged that the group was also "highly cash-generative", with little capital investment required to support its continued growth over the coming years.
Supreme share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210918 16:34:21